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6-hydroxydopamine (6-OHDA) is one of the most commonly used toxins for modeling degeneration of dopaminergic
(DA) neurons in Parkinson's disease. 6-OHDA also causes axonal degeneration, a process that appears to precede the
death of DA neurons. To understand the processes involved in 6-OHDA-mediated axonal degeneration, a microdevice
designed to isolate axons fluidically from cell bodies was used in conjunction with green fluorescent protein (GFP)-labeled
DA neurons. Results showed that 6-OHDA quickly induced mitochondrial transport dysfunction in both DA and non-DA
axons. This appeared to be a general effect on transport function since 6-OHDA also disrupted transport of
synaptophysin-tagged vesicles. The effects of 6-OHDA on mitochondrial transport were blocked by the addition of the
SOD1-mimetic, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP), as well as the anti-oxidant N-acetyl-cysteine
(NAC) suggesting that free radical species played a role in this process. Temporally, microtubule disruption and autophagy
occurred after transport dysfunction yet before DA cell death following 6-OHDA treatment. The results from the study
suggest that ROS-mediated transport dysfunction occurs early and plays a significant role in inducing axonal degeneration
in response to 6-OHDA treatment.
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Genetic, imaging and environmental studies of Parkinson’s
disease (PD) have revealed early problems in synaptic
function and connectivity, suggesting that axonal impair-
ment is an early, dominant feature of this disorder [1]. For
example, assessment of available patient positron emission
tomography data suggests that at the time of motor symp-
tom onset there is a far greater loss of striatal dopamin-
ergic (DA) terminals than substantia nigra DA neurons
[1]. Moreover, post mortem studies show widespread
axonal pathology that precedes the loss of cell bodies
[2,3]. Such data support the notion that nigral neurons
degenerate through a “dying back” axonopathy [4,5].
Animal models of PD-linked genes also point to axonal
degeneration as an initiating factor. For example, transgenic
mice expressing the PD-linked R1441G LRRK2 mutation
have decreased DA terminal fields together with increased
dystrophic processes and abnormal axonal swellings, find-
ings consistent with DA axonopathy [6]. In addition,* Correspondence: sakiyama@wustl.edu
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unless otherwise stated.reduced axonal transport is seen with α-synuclein mutants,
which accumulate in the cell soma when overexpressed in
cortical neurons [7]. Emerging data also support a role in
which the PD-linked genes, PINK1 and Parkin, regulate
mitochondrial transport [8]. Studies in cell lines and hippo-
campal and cortical neurons show that PINK1 is stabilized
on the outer mitochondrial membrane in response to
depolarization. Stabilized PINK1 recruits Parkin, which
subsequently triggers mitophagy (the autophagy of mito-
chondria). PD-linked mutations appear to disrupt this
process allowing damaged mitochondria to accumulate and
then impair axonal transport and initiate neurodegenerative
processes [8].
Studies using Parkinsonian toxins also implicate mito-
chondrial trafficking and axon integrity in the loss of DA
axons. Using specially-designed compartmented chambers
and isolated axon preparations derived from transgenic
GFP-tagged DA neurons, we discovered that the PD-
mimetic toxin MPP+ rapidly (<1 h) and selectively de-
creased mitochondrial movement in DA axons [9,10].
In support of the notion that damaged mitochondria
are re-routed to the cell body for disposal, anterograde
traffic was decreased whereas retrograde trafficking wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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depolarization and immobility (30–60 min), MPP+ treat-
ment led to the induction of autophagic markers such as
LC3 puncta (microtubule-associated protein 1, light chain
3; also known as ATG8) [11] (3 h), and then the disrup-
tion of microtubule tracks starting at 6 h (beading) peak-
ing between 18–24 h with extensive fragmentation [10].
Thus in MPP+-mediated axonal impairment, compro-
mised mitochondria are an early event triggering down-
stream sequelae leading to autophagy.
6-hydroxydopamine (6-OHDA) is another widely used
Parkinsonian toxin that induces degeneration of DA neu-
rons [12]. 6-OHDA has been shown to disrupt complex I
of the mitochondrial electron transport chain and increase
generation of reactive oxygen species (ROS) that contrib-
utes to an apoptotic form of cell death. However, it is not
known how 6-OHDA induces axonal damage.
Using our newly described compartmented microde-
vices [9] we studied the effects of 6-OHDA on various
processes using murine mesencephalic cultures. Here we
show that 6-OHDA decreases mitochondrial and vesicular
movement in DA axons and explore potential mecha-
nisms underlying these effects.Figure 1 6-OHDA rapidly decreases mitochondrial movement in DA axo
control and 6-OHDA treated axons. DA-GFP cultures (Top panels) grown in m
imaged 30 minutes after treatment with 6-OHDA. Resulting kymographs are s
in the bottom panels: blue lines denote anterograde movement and red line
of C) moving mitochondria (n = 4–5 devices per group with 4–5 axons analyz
as described [10] (n = 60–80 mitochondria per group). In C and D, data are re
6-OHDA in somal compartment.Materials and methods
Cell culture
Microdevice fabrication and cell culture were performed
as previously described [9,10]. The width of the micro-
channels for the microdevice (Figure 1A) was decreased
to 5 μm from 10 μm to increase the probability of observ-
ing singly labeled axons and to limit axonal bundling.
Other dimensions of the microdevice were unchanged
from those previously reported. Midbrain tissues were
harvested from E14 Tg(TH-EGFP) DJ76GSAT transgenic
mouse embryos (Jackson Laboratories, Bar Harbor, ME).
Animal procedures were performed in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals. All GFP positive tissues were
pooled. For seeding, 60,000 cells were plated per somal
compartment in DMEM/F12 (Invitrogen, Carlsbad, CA)
with 10% FBS (Invitrogen) supplemented with 1× B-27
(Invitrogen) and 100 I.U. penicillin/100 μg/mL strepto-
mycin (CellGro, Manassas, VA). Cells were concentrated
via centrifugation to obtain a final loading volume of 5 μL.
Cells were fed with fresh Neurobasal media (Invitrogen)
and supplemented with 0.5 mM glutamine (Sigma-Aldrich,
St. Louis, MO) and 1× B27 every other day. On DIV 5, thens. A) Diagram of microdevice B) Axonal movement of mitochondria in
icrodevices and transduced with MitoDsRed2 (Middle panels) were
hown below. For additional clarity tracks of moving particles are depicted
s indicate retrograde trafficking. Scale bar indicates 10 μm. Quantification
ed per device) and D) mitochondrial speeds. The latter were calculated
presented as mean ± SEM, * + indicates p < 0.05 versus control and
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final concentration: 5 μM) to limit glial proliferation.
Netrin I (300 ng/mL, R&D Systems, Minneapolis, MN)
was added into the axonal compartment as a chemo-
attractant. Addition of toxin is as follows: from an initial
stock of 6-OHDA (Sigma-Aldrich), serial dilutions were
performed using deoxygenated water to a volume of
100 μL (per compartment) for a final concentration of 40
(for assessing autophagy) or 60 μM, which was used for all
other experiments.
Mitochondrial and synaptic vesicle labeling
Transport was assessed on DIV 12 or 13 by adding
6-OHDA to both or either axonal/somal compartment. To
label mitochondria, a plasmid containing mitochondrially-
targeted DsRed2 was generated by inserting a mitochondrial
targeting sequence (MLSLRQSIRFFK, the signal peptide of
COX IV) in front of DsRed2 (Clontech, Mountain View,
CA). The mitoDsRed2 was then subcloned into a
FUGW lentiviral expression vector provided by Dr. Jeffrey
Milbrandt (Washington University in St. Louis). The lenti-
virus was generated in HEK293T cells using procedures
previously described [13]. Cells were transduced with the
virus on DIV 2 for 5–6 hours. By limiting viral transduc-
tion to obtain 60-70% labeling efficiency, many more sin-
gly labeled axons per microchannel were observed. A
lentivirus for labeling synaptic vesicles was generated
using a plasmid containing synaptophysin fused in frame
with cerulean (provided by Dr. Rachel Wong, University
of Washington Seattle).
Microtubule structure
The integrity of microtubules was assessed by immuno-
staining with antibodies against acetylated tubulin (AcTub;
Sigma-Aldrich) and tyrosine hydroxylase (TH) (Pel-Freeze
Biological, Rogers, AR) after treatment with 6-OHDA in
the axonal compartment. Axons with three AcTub breaks
or more were considered damaged and the number as a
percentage of total axons in TH-positive and negative
axons was determined.
Retrograde degeneration study
On DIV 13, the axonal compartment was treated with
6-OHDA and then cell death was assayed by labeling with
propidium iodide (1 μg/mL, Sigma-Aldrich) at 24 and
48 hours. Fluorescent and bright field images were taken
of cell bodies within 350 μm of the microchannel opening
in the somal compartment. Cell death was quantified by
calculating the fraction of propidium iodide positive cells.
Autophagy
On DIV 5–6, cells were transfected with a GFP-tagged
LC3 expression vector provided by Dr. Chris Weihl [14].
24 hours after transfection, cells were treated with6-OHDA for the specified time, fixed, and stained with
antibodies against tyrosine hydroxylase (TH) (Pel-Freeze
Biological, Rogers, AR). Cells with LC3-GFP puncta were
counted and compared to the total number of LC3-GFP
positive cells in TH-positive and negative ones.
Confocal imaging
Time lapse images of mitochondrial movement were
taken using a Zeiss LSM510 Meta NLO Multiphoton
System (Carl Zeiss, USA) on Axiovert 200 M inverted
microscope with a 40× water objective [C-Apochromat
40×/1.2 W Corr.1.2 numerical aperture, collar correction
(0.14-0.18)]. The microscope contains a heated stage
which includes a Pecon CTI-Controller 3700 for regulat-
ing 5% CO2 (Zeiss, USA) and a Pecon TempControl 37–
2 digital (Zeiss) for heating the stage to 37°C for the dur-
ation of the image recordings. A total of sixty images at
5 s intervals (mitochondria and vesicles) or 180 images
at 2 sec intervals (vesicles) were recorded and then used
to generate kymographs for measurement of transport.
Filters used for visualizing the fluorescent markers in-
cluded a 488 nm argon laser and 505 nm long pass
emission filter (GFP), 543 nm HeNe laser and 560 nm
long pass emission filter (MitoDsRed2) and 458 nm
argon laser and 466–514 meta emission filter (Syn-Cer).
Kymograph analysis of moving particles
Kymographs generated using Image J (NIH, Bethesda,
MD) were analyzed as described previously [10]. Time
lapse images were imported into ImageJ and then the
image was split into individual channels. A threshold
image of the mitochondrial channel was used for analysis.
A segmented line was then used to select the region of
interest. An add-on to ImageJ called Multiple Kymographs
was then used to generate each kymograph derived from
the region of interest. Each diagonal line upon a kymo-
graph represented a moving particle while the straight
lines represented nonmoving particles. The angle and
length of each line was then used to calculate the direction
and speed of the moving mitochondria [10].
Mitochondrial membrane potential and size
Cells were loaded with 25 nM of Tetramethylrhodamine
ethyl-ester (TMRE, Invitrogen) for 25 minutes prior to
imaging. Changes in mitochondrial membrane potential
were determined by differences in TMRE membrane
potential along an axonal region of interest before and
after treatment with 6-OHDA [15]. Mitochondrial cross
sectional area was estimated by mitoDsRed2 fluores-
cence using Image J’s particle analysis.
Statistical analysis
Statistical analysis was performed using Statistica (Statsoft,
Tulsa, OK). One way ANOVA, followed by Scheffe's F test
Lu et al. Molecular Neurodegeneration 2014, 9:17 Page 4 of 11
http://www.molecularneurodegeneration.com/content/9/1/17or Student’s t-test were used to determine statistical sig-
nificance. P values below 0.05 were determined to be sta-
tistically significant.
Results
Mitochondrial movement decreased in DA and non-DA axons
To investigate how 6-OHDA influences axonal mitochon-
drial transport, we used a microdevice to isolate the axons
and labeled the mitochondria using a lentivirus expressing
mitochondrially targeted DsRed2 to allow visualization in
live cells. Initial dose response experiments using cultured
DA neurons suggested that 60 μM 6-OHDA led to ~60%
cell death after 24 h [16]. Using this dose, there was a 50%
decrease in DA mitochondrial motility 30 minutes after
6-OHDA treatment in the axonal compartment (Figure 1B,
C). Taking advantage of the fluidic isolation between the
somal and axonal compartment, experiments were per-
formed where only the somal compartment was treated
with 6-OHDA to determine whether there was an antero-
grade effect on axonal mitochondrial transport. After 30 mi-
nutes, DA mitochondrial motility or movement speed
within the microchannels showed no statistically significantFigure 2 6-OHDA rapidly decreases mitochondrial movement in non-DA
treated axons. Non-GFP positive axons (non-DA; Top panels) that were labeled
after treatment with 6-OHDA. Resulting kymographs are shown below. For add
blue lines denote anterograde movement and red lines indicate retrograde traf
in both anterograde and retrograde directions (n = 3–4 devices per group from
motile mitochondria. The latter were calculated as described [10] (n = 90–120 m
*: indicate p < 0.05 versus control.change compared to vehicle-treated controls (Figure 1C,D).
Finally, of the mitochondria that were still motile, there
were no significant differences in transport speed in either
an anterograde or retrograde direction (Figure 1D).
Because 6-OHDA is easily oxidized in vitro to p-quinones
and ROS species such as hydrogen peroxide, 6-OHDA may
exert its toxic effect via an extracellular mechanism without
the need for uptake via the dopamine transporter [17]. In
fact, we have previously shown that even small doses and
short time treatments with 6-OHDA lead to death of DA
and non-DA neurons in culture [16]. Not surprisingly then,
mitochondrial transport in non-DA axons was also signifi-
cantly decreased in terms of total mitochondrial motility
without an effect on anterograde or retrograde velocities
(Figure 2). Taken together, 6-OHDA led to a 50% decrease
in mitochondrial motility 30 min after treatment in both
DA and non-DA axons.
6-OHDA decreases mitochondrial membrane potential
but does not affect mitochondrial size
Mitochondrial membrane potential is a commonly used
parameter for determining mitochondrial health and mayaxons. A) Axonal movement of mitochondria in control and 6-OHDA
with MitoDsRed2 (Middle panels) were selected for imaging 30 minutes
itional clarity tracks of moving particles are depicted in the bottom panels:
ficking. Scale bar indicates 10 μm. Quantification of B)moving mitochondria
with 3–5 axons analyzed per device) and C) mitochondrial speeds of
itochondria per group). In B and C, data are represented as mean ± SEM,
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cessation of mitochondrial movement. Therefore to assess
relative changes in mitochondrial membrane potential, we
assessed the ability of mitochondria to accumulate a
membrane voltage sensitive dye, TMRE, and determined
membrane depolarization by a decrease in TMRE fluores-
cent intensity. Thirty minutes after treatment with
6-OHDA, a significant decrease in TMRE fluorescence was
observed in both DA-GFP axonal mitochondria and non-
GFP mitochondria (Figure 3A,B). To determine whether
mitochondrial fragmentation plays a role in cessation of
movement, mitochondrial cross-sectional area was mea-
sured using the Image J particle analysis program. As
TMRE fluorescence is lost upon membrane depolarization,
it cannot be used to accurately measure changes in relative
mitochondrial morphology. Instead, mitoDsRed2 was used
to measure mitochondrial size. Even after 1 hour of
6-OHDA treatment there was no significant difference
between cross-sectional areas of the control and toxin-
treated groups (Figure 3C).
6-OHDA decreases axonal transport of synaptic vesicles
Mitochondria are not the only cargo being transported
along the axon. Using standard bright-field microscopy,
it is common to see many particles moving bi-
directionally along the axon. However, when assessingFigure 3 6-OHDA rapidly depolarizes mitochondria in both DA and n
TMRE (25 nM), axons were assessed after they had exited the microdevice
mitochondrial membrane potential (ΔΨm) in DA and non-DA axons. Data
axons per group). ** indicates p < 0.001 versus control. C) Quantification of
with 6-OHDA. Data indicate mean ± SEM.particle movement in our microchannels, the particles
tend to blend into the shadow of the microchannels, as
axons adhere to the channel sides, hence particle move-
ment cannot be measured using a standard bright-field
microscopy. Therefore, to determine whether 6-OHDA
specifically disrupts mitochondrial transport or whether
it may affect transport of other axonal cargo, movement
of synaptic vesicles was assessed with a synaptophysin-
cerulean marker. Previous reports from this lab showed
that synaptophysin-cerulean marked small rapidly mov-
ing vesicles that did not co-localize with mitochondria
[10]. Similar to the decrease in mitochondrial motility,
after 30 minutes of treatment with 6-OHDA the move-
ment of synaptic vesicles in both the anterograde and
retrograde direction was reduced by 60-70% (Figure 4).
Due to the low number of moving particles, meaningful
velocity data could not be obtained from measuring the
remaining motile particles. These findings show that
6-OHDA affects axon transport machinery resulting in
decreased axonal transport of two important cargoes,
synaptic vesicles and mitochondria.
6-OHDA damages microtubule tracks after 6 hours and
induces retrograde degeneration
Destabilization of the cytoskeleton tracks along which
transport occurs could potentially be a causative factoron-DA axons. A) To ensure rapid, even labeling of mitochondria with
channels. Scale bar indicates 10 μm. B) 6-OHDA significantly decreased
indicate mean ± SEM from four independent experiments (n = 18–30
cross-sectional area of DA mitochondria before and after treatment
Figure 4 6-OHDA also decreases synaptic vesicle movement in DA axons. A) DA-GFP cultures (Top panels) in microdevices were transduced
with Syn-Cer lentivirus (Middle panels) at DIV2. Vesicular movement was assessed on DIV12–13 before and after toxin treatment. Resulting kymo-
graphs are shown below. Because of the smaller size of vesicular particles and the relative “dimness” of the cerulean emission, tracks of moving
particles are shown in bottom panels for clarity. Red represents retrograde movement whereas blue is anterograde trafficking. B) Quantification of
moving vesicles was determined as described in Materials and Methods. Scale bar: 5 μm. Mean ± SEM, total of 8 (control) and 8 (6-OHDA-treated)
axons from 5–7 devices per group. * indicates p < 0.05 versus control.
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along the axon. Microtubules are the primary tracks along
which axonal transport occurs. Therefore to assess micro-
tubule integrity, we stained for acetylated tubulin (AcTub),
a marker associated with stabilized microtubules. ControlFigure 5 6-OHDA induces microtubule disruption and retrograde deg
measuring tubulin fragmentation in DA cultures treated with 6-OHDA at th
AcTub and TH. Significant fragmentation of AcTub is not seen prior to 6 ho
fragmented AcTub staining were quantified. One hundred to three hundre
group. Scale bars indicate 10 μm. Bars represent mean ± SEM. ** indicates p
microdevices were treated with 6-OHDA for 24 or 48 hours. Subsequently,
iodide (PI) and then imaged 30 minutes later to assess cellular degeneratio
6-OHDA treatment) or 24 hour after 6-OHDA cultures. D) Quantification of
indicates 40 μm. Data are represented as mean ± SEM, *indicates p < 0.05 vaxons showed smooth and continuous AcTub staining at
all time points whereas axons treated with 6-OHDA only
remained intact for about 6 hours (Figure 5A,B). By
24 hours, more than 80% of DA (Figure 5B) and non-DA
axons (83 ± 4%) showed a significant number of breakseneration in vitro. A) Integrity of microtubule tracks was assessed by
e indicated times and then fixed and stained with antibodies against
urs, but is readily apparent at 24 hours. B) TH positive axons with
d DA-GFP axons were counted per dish and 4–5 dishes were used per
< 0.001 versus control. C) The axonal side of cultures grown in
the cell body compartment was treated with 1 μg/ml of propidium
n. Note very little PI staining is seen in control (48 hours without
cell death using propidium iodide. n = 4 devices per group. Scale bar
ersus control.
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microtubule destabilization is not a main causing factor
for the early effect of 6-OHDA on axonal transport.
In vivo, 6-OHDA induces retrograde degeneration of
DA neurons following injection within the striatum
[18,19]. Normally, whether this occurs in vitro is impos-
sible to assess given the difficulty in assigning processes to
cell bodies, however, this is readily done in the compart-
mented chambers. Thus, to assess whether this form of
retrograde degeneration also occurs in vitro and deter-
mine the time course for when it occurs, 6-OHDA was
applied only to the axonal chamber and cell death was
assayed using propidium iodide at 24 and 48 hours post
treatment. While the majority of axons showed fragmen-
tation of acetylated microtubules at 24 hours (Figure 5A,
B), no significant cell death was detected at this time in
the somal compartment near the microchannels. A signifi-
cant increase in cell death was only measured 48 hours
after 6-OHDA treatment (Figure 5C,D). These results
confirm those shown in vivo and highlight the utility of
the microdevice system to model and study retrograde
neuronal degeneration.
6-OHDA induces autophagosome formation
Damaged mitochondria can be harmful and degraded by
a form of autophagy known as mitophagy. Successful
removal of damaged mitochondria could be critical for
maintaining axonal health and limiting secondary dam-
age. Improper regulation of the mitophagy process could
adversely affect neuronal health. Previously, 6-OHDA
has been shown to induce autophagy in rat models [19]
and cell lines [20]. To determine whether 6-OHDA
could also induce autophagy and whether it could be a
cause for mitochondrial movement in axons from mur-
ine mesencephalic neurons in vitro, the appearance of
LC3, an autophagy marker, was assessed. Under control
conditions, LC3-GFP exhibited a continuous fluores-
cence within the cytosol. However, 9 hours after
6-OHDA treatment, LC3 fluorescence took on a punc-
tate appearance thought to represent its aggregation on
membranes of autophagosomes (Figure 6A,B). There
was a significant increase in the percentage of LC3-GFP
positive puncta in nonDA neurons with only a trend to-
ward increased positive puncta in DA neurons, suggest-
ing distinctive roles of autophagy in the 6-OHDA model.
Also, it appears that the formation of autophagosomes is
a later event, which occurs after disruptions in axonal
transport.
NAC and MnTBAP rescue mitochondrial transport
6-OHDA has been shown to inhibit mitochondrial com-
plex I activity [21] and has been suggested to induce cell
death via oxidative stress primarily by increased ROS for-
mation [12]. It has also been found that ROS scavengerswere potent in protecting cell bodies against the toxic
oxidative byproducts of 6-OHDA [22]. To investigate
whether oxidative stress induced by ROS formation also
plays a role in disrupting axonal transport of mitochon-
dria, we investigated whether anti-oxidants such as NAC
and MnTBAP could rescue this early event in axonal
degeneration. In addition, we also investigated whether
EGTA could rescue mitochondrial transport disruption
since calcium signaling plays an important role in axon
degeneration [23]. Consistent with the notion that block-
ing ROS prevents subsequent impairment of mitochon-
drial processes [24], both NAC and MnTBAP protected
DA mitochondria from transport impairment after treat-
ment with 6-OHDA (Table 1). NAC also rescued synaptic
vesicle motility (vesicle motility: 23.8 ± 2% compared to
6-OHDA: 7.6 ± 1.2%, p < 0.05). In contrast, EGTA did not
protect against the loss of mitochondrial mobility suggest-
ing that calcium did not play a role in this injury, at least
at early time points (Table 1).Discussion
The use of novel microdevices to isolate axons from cell
bodies combined with real time imaging of axonal mito-
chondria and synaptic vesicles provided new insights into
the temporal sequence of cellular changes underlying 6-
OHDA-mediated dysfunction (Figure 6C). The present
findings demonstrated that (1) 6-OHDA rapidly blocked
(<30 min) mitochondrial trafficking in DA axons, a process
accompanied by a loss in mitochondrial membrane poten-
tial; (2) the effects of 6-OHDA in vitro were not selective
for DA mitochondria as non-DA mitochondria were
equally affected; (3) remaining motile mitochondria
exhibited decreased movements in anterograde direction;
(4) 6-OHDA also decreased axonal transport of synaptic
vesicles within 30 min; (5) both mitochondrial and vesicu-
lar transport could be rescued by pre-treatment with anti-
oxidants, such as NAC; (6) 6-OHDA affected microtubule
tracks in axons 6–9 hr after axonal transport ceased
and death was observed in cell bodies after 48 hours.
(7) 6-OHDA caused the formation of autophagosomes after
9 hr of treatment. Taken together these data demonstrate
that 6-OHDA induces cell death via a retrograde dying
back process that can be blocked by free radical scavengers.
Widely used as an animal model of PD, 6-OHDA quickly
oxidizes to form a variety of free radical species which can
lead to toxic sequelae, such as DNA damage [25] and
oxidation of proteins [26-28]. Although oxidative protein
damage leads to ER stress and the upregulation of the
unfolded protein response [29,30], this appears to serve as
a protective measure in DA neurons [25]. Instead, DNA
damage leads to activation of a p53- and Puma-dependent
apoptotic cascade in vivo and in vitro; loss of p53 and
Puma rescues 6-OHDA-mediated cell death [25,31,32].
Figure 6 Autophagy precedes cell death in midbrain neurons following 6-OHDA treatment. A) Autophagy was assessed by introducing a
GFP-tagged LC3 expression clone at DIV6 and treating midbrain cultures 1 d later with 6-OHDA. LC3-positive puncta (arrows) were assessed by
GFP fluorescence in representative neurons in control and after toxin treatment. B) The number of cells with at least three LC3-GFP puncta were
counted and expressed as percentage of all neurons that were LC3-GFP positive, regardless of whether the LC3-GFP signal in these neurons was
diffuse or punctated. Scale bar indicates 10 μm. Mean ± SEM from 3 independent experiments (n = 3–5 per group), *p < 0.05 versus control.
C) Timeline of 6-OHDA induced events.
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port impairment, retrograde dying back and loss of axonal
integrity? Interestingly, in vivo studies using 6-OHDA to
damage the nigrostriatal projection showed that activation
of the Akt/mTOR pathway could block apoptosis, pre-
serve DA cell bodies, prevent autophagy and suppress
retrograde axon degeneration [19]. Mechanistically, these
data underscore the importance of preserving axonal
function. The present in vitro findings further emphasize
very early events that occur in the axonal compartmentthat set the stage for later events including the loss of con-
nectivity and ultimately cell death. It should be stressed
that the direction of degeneration is also an important
caveat and differences may exist between anterograde and
retrograde models of degeneration, particularly for degen-
eration in the nigrostriatal region. For example while
many Wlds studies have shown that it delays and protects
against axonal loss in anterograde degeneration, it does
not confer axonal protection against retrograde degener-
ation [33-35]. The model and findings of this study are
Table 1 Effects of antioxidants and calcium chelation on
6-OHDA-disrupted DA mitochondrial transport
Motile Mitochondria
Control 24.6 ± 1.3%*
6-OHDA 10.3 ± 2.2%
+NAC 25.7 ± 3.3%*
+MnTBAP 28.2 ± 6.5%*
+EGTA 8.34 ± 3.9%
Data indicates mean ± SEM. * indicate p < 0.05 versus 6-OHDA. [NAC] = 2.5 mM,
[MnTBAP] = 100 μM, [EGTA] = 2.5 mM.
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dying back nature of Parkinson's and other neurodegener-
ative diseases. Akin to the in vivo results, inclusion of
toxin in the somal compartment did not immediately lead
to anterograde loss of axonal transport (Figure 1C)
whereas axonal transport was rapidly compromised in the
retrograde direction (Figure 1). Although we have not yet
tested the role of Akt/mTOR, we would predict that these
cascades are downstream of ROS generation given the
timing by which autophagy is stimulated (9 h; Figure 6)
and that microtubules exhibit fragmentation (24 h;
Figure 5).
Because the anti-oxidants NAC and SOD1 mimetics
rescued 6-OHDA-immobilized mitochondria, it is likely
that axonal transport dysfunction and degeneration is
due to the increased generation of ROS species affecting
general transport processes. The latter might include
oxidation of the transport proteins themselves or oxida-
tion of an adaptor protein responsible for connecting
the motor protein to the organelle. For example, impair-
ment of motor proteins such as kinesin-1disrupts axonal
transport and induces axonal degeneration [36]. Adaptor
proteins such as Miro and Milton can be oxidized but
are also regulated by calcium changes that can affect
their binding to each other. Given the lack of effect of
EGTA (Table 1) and previous experiments showing no
change in calcium levels in response to 6-OHDA [26],
that makes this hypothesis less likely to be correct.
Alternatively, 6-OHDA-generated ROS might block
mitochondrial ATP production leading to a loss of
energy required by the motor proteins to function [37].
Consistent with this notion, a recent report showed that
hydrogen peroxide led to the loss of mitochondrial
transport in hippocampal neurons, an effect mimicked
by blocking ATP synthesis [38]. Previously we showed
that this was not the case in DA axons treated with
another widely used PD-mimetic, MPP+ [10]. Surpris-
ingly, despite being a Complex I inhibitor, MPP+ also
rapidly blocked mitochondrial transport via a redox
sensitive process and not via ATP loss [10]. The extent
to which ATP deficiency mediates 6-OHDA effects in
the trafficking of mitochondria remains to be tested.Although 6-OHDA and MPP+ are often lumped
together as PD-mimetics, their effects on neurons and
in particular DA neurons are quite unique. Although
both toxins lead to the death of DA neurons in a pro-
tein synthesis-, p53-, and PUMA-dependent manner
[16,25,29,39], the downstream signaling pathways diverge
in many ways [40]. In terms of axonal impairment,
6-OHDA and MPP+ both lead to the loss of neurites
prior to cell body death [10,16,40,41] as well as
mitochondrial dysfunction and loss of motility in DA
axons. In contrast to 6-OHDA, MPP+ exhibits a more
specific effect on mitochondrial movement that cannot
be rescued by ROS scavengers, such as MnTBAP (SOD
mimetic); MPP+ could exert its toxicity by disrupting
the redox state (e.g. generation of glutathione or hydro-
gen peroxide) of the mitochondria after internalization
whereas 6-OHDA could directly auto-oxidize to ROS,
such as hydrogen peroxide both inside and outside of a
cell [10]. The present findings show that 6-OHDA-
generated ROS affects many axonal transport processes
including mitochondrial and synaptic vesicle trafficking.
Taken together, these data further emphasize that 6-
OHDA and MPP+ impair axons and cell bodies by
distinct cellular mechanisms.
The PD-linked genes, Pink1 and Parkin appear to play
important roles in regulating mitochondrial dynamics
such as movement and morphology as well as mitochon-
drial removal after damage [42-45]. Many studies espe-
cially in neuroblastoma cells show that mitochondrial
membrane depolarization stabilizes Pink1 on the outer
mitochondrial membrane leading to the recruitment of
Parkin, cessation of movement and the rapid induction
of autophagy [46]. Previously we showed that MPP+
depolarized DA mitochondria and blocked trafficking
within 1 hr following treatment; autophagy was ob-
served shortly thereafter (3 hr; [10]). Despite the rapid
depolarization and cessation of mitochondrial movement
in 6-OHDA-treated axons, autophagy was observed after
9 hrs (Figure 6). It is unclear why this delay for non-DA
neurons or even less for DA neurons exists since damaged
mitochondria could serve as a source for leaking ROS that
can further exacerbate the oxidative damage to the axon.
The role of autophagy in 6-OHDA has been inconsistent
in the literature [47,48]; one study showed that blocking
autophagy helped protect SH-SY5Y cells against 6-OHDA
toxicity, whereas the other study showed that regulation
of 6-OHDA induced autophagy had no effect on the death
of SK-N-SH cells derived from SH-SY5Y cells, a human
neuroblastoma cell line. Although not significant, there
was a clear trend towards autophagosome formation in
DA neurons. Also, we noted differences in the appearance
of LC3 puncta between DA and nonDA neurons, which
calls for further investigation to determine the characteris-
tics of autophagy in primary DA neurons.
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could ROS generated from mitochondrial damage or
6-OHDA oxidation limit intra-axonal recruitment of Pink1
to the mitochondria or its stabilization? Perhaps, as sug-
gested above, it is a loss of ATP that impairs organelle
movement and Pink1/Parkin are only involved at later time
points if at all. Other pathways exist that trigger autophagy,
and it may be that these represent alternative, yet slower
mechanisms to ensure axonal removal of damaged mito-
chondria or vesicles [49,50]. In any case, the delay in the
onset of autophagy suggests that damaged mitochondria
are remaining within the axons and are not being removed
which may contribute to further axonal impairment due to
steric hindrance. Moreover, just the appearance of LC3
puncta is not indicative of the successful removal of dam-
aged organelles, since the formation of an autolysosome is
required for complete removal of damaged mitochondria.
Excessive autophagosome formation without proper traf-
ficking could also lead to transport blocks.
It is clear that axonal transport disruptions play an
early and important role in 6-OHDA induced axonal
degeneration. While differences exist between 6-OHDA’s
and MPP+’s effects on axonal transport, the observation
that these two widely used toxin models converge on
early dysregulation of mitochondrial transport prior to
other events such as microtubule fragmentation points
to the importance of maintaining the health of the
axonal compartment. While it remains to be seen
whether other PD toxin models, such as paraquat or
rotenone induce similar patterns of axonal impairment
in midbrain DA axons, maintenance of mitochondrial
transport could bridge the gap between different causes
of axonal degeneration and suggest a common thera-
peutic strategy. Improper trafficking of vital organelles,
such as mitochondria and other signaling vesicles may
lead to energy deficits, exacerbate oxidative stress, ionic
disruption, accumulation of misfolded proteins, or the
inability of retrograde signaling molecules to reach
their somal targets. All of these processes could lead to
the activation of axonal death pathways. The discovery
of Sarm1, a protein required for the activation of
injury-induced axonal degeneration points to the exist-
ence of one such axonal death signaling pathway [51].
Whether Sarm1 or an axon regenerative pathway, such
as mTOR [52,53], is applicable to axonal impairment in
PD remains to be addressed. The development of
microdevices provides a tool to rigorously characterize
cell populations such as neurons whose extended, com-
partmented morphology renders previously intractable
problems solvable. These new technologies continue to
enhance and expand the available toolset for under-
standing key biological processes in order to develop
better therapies for patients suffering from major
neurological disorders.Conclusions
Using a microplatform, we showed that 6-OHDA, one of
the most commonly used parkinsonian mimetics, disrupts
the motility of mitochondria and synaptic vesicles in DA
axons early in the process of axonal degeneration. In
addition, local exposure of axons to 6-OHDA was enough
to induce axonal loss and eventually, cell death. The
rescue of 6-OHDA induced mitochondrial transport
dysfunction by anti-oxidants suggests that ROS or dis-
ruption of cellular defenses against ROS may contribute
significantly to the dying-back form of degeneration
seen in Parkinson's disease.
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